The company said that the Canadian patent provides protection covering Javelin’s intranasal ketamine drug into 2015. Generally, Canadian ketamine patent covers the use of nasally administered ketamine to treat chronic pain, as well as devices used to treat pain by nasal administration of ketamine.
Daniel Carr, Javelin’s CEO and chief medical officer, said: “This new patent, directed to Javelin’s anticipated commercial formulations of PMI-150, encompasses a broad range of claims that enhance our intellectual property portfolio and commercial protections for PMI-150 in Canada. We believe that upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain.”